BioSpace News Archive

As the COVID-19 pandemic remains entrenched in the United States, demand for effective and comfortable face masks continues to climb. To meet the current and future needs, Creative Home Ideas/YMF, an American company with 35 years of experience in developing and manufacturing, has launched a new division, Germ Tech,

Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development, is pleased to announce that the Corporation is set to accelerate its European activities.

One of the largest active Phase 3 clinical trials in metastatic pancreatic cancer, completes target enrollment ahead of schedule

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the initiation of a Phase 2 proof-of-concept study using TNX-102 SL for treatment of alcohol use disorder (AUD). The program in AUD is expected to qualify for the 505(b)(2) pathyway for FDA approval. “We are ex

The Parkinson’s Foundation today announced a $3.4 million investment across 34 research grants to advance promising Parkinson’s disease (PD) research. Grants support Parkinson’s research across a variety of

Thermo Fisher Scientific, the world leader in serving science, today unveiled its next-generation Thermo Scientific Apreo 2 Scanning Electron Microscope (SEM), a high-performance field emission SEM that takes automation to

Thermo Fisher Scientific today released the Thermo Scientific Helios 5 Plasma Focused Ion Beam (PFIB) DualBeam and the Thermo Scientific Helios 5 Hydra DualBeam focused ion beam scanning electron microscopes (

Biotech company provides test results within 24 hours for early virus detection in long-term care facilities, schools

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the pricing of the previously announced underwritten registered public offering of 4,000,000 of its common shares at a price to the public of $5.00 per share. DiaMedica has also granted the underwriters a 30-day option to purchase up to an additional 600,000 common shares, at the public offering price, less underwriting discoun

First and only FDA-cleared assay for MRD in CLL, multiple myeloma and ALL CLL clearance includes testing in blood; Adaptive collaborating with LabCorp ® and Phlebotek Solutions ® to provide clonoSEQ patients convenient options and safe access to blood draws at home or at LabCorp Patient Service Centers A Media Snippet accompanying this announcement is available by clicking on the image or link below: SEATTLE, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (N